English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recently we developed [ 18 F] 4-(2-fluoroethoxy)-2 H -chromen-2-one as a novel  18 F myocardial perfusion imaging radiotracer. It was synthesized in good radiochemical yield (&gt;90%). The total time from radiosynthesis to its purification was less than 40 min, with excellent radiochemical purity (≥99%). It showed good stability over a period of 5 h at room temperature. The partition coefficient (log  P ) of radiotracer was found to be 2.70, suggesting the lipophilic nature of radiotracer.  Ex vivo  biodistribution study of radiotracer in normal Wistar rats for 30 min post-injection, demonstrated a good heart uptake (&gt;1.3% ID/g) and favorable pharmacokinetics. Additionally, the radiotracer showed significant excretion (&gt;11% ID) by liver, which is indicative of its rapid clearance. Further,  in vivo  biodistribution study of radiotracer in New Zealand White rabbit provided the clear PET/CT images of cardiomyocytes and myocardial perfusion. All these experimental findings suggest that [ 18 F] 4-(2-fluoroethoxy)-2 H -chromen-2-one could be used as a potential hit for myocardial perfusion imaging.

Radiosynthesis and preclinical evaluation of [ 18 F] 4-(2-fluoroethoxy)-2 H -chromen-2-one as a novel myocardial perfusion imaging agent